<DOC>
	<DOCNO>NCT03051945</DOCNO>
	<brief_summary>Demonstrate acute effect ketamine endogenous µ-opioid neurotransmission human .</brief_summary>
	<brief_title>Endogenous Opioid Modulation Ketamine</brief_title>
	<detailed_description>This study test hypothesis rapidly-acting antidepressant ketamine improve core depressive symptom acutely activate brain 's endogenous µ-opioid system .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Endorphins</mesh_term>
	<criteria>age 1865 diagnosis DSMIV/DSM5 major depressive disorder current moderatetosevere depressive episode Patient Health Questionnaire ( PHQ9 ) total score ≥ 10 PHQ9 item score ≥ 2 `` Little interest pleasure '' PHQ9 item score ≥ 2 `` Feeling , depress , hopeless '' medical documentation depression least 2 month chronic depression : current episode duration &gt; 2 year high medication resistance : nonresponse &gt; 3 adequate trial current episode moderatetosevere DSM5 substance use disorder ( past year ) cognitive disorder ( lifetime ) posttraumatic stress disorder ( past year ) obsessive compulsive disorder ( past year ) personality disorder ( past year ) positive urine drug screen history psychotic symptom significant neurologic disorder injury breastfeed pregnancy imminent suicide risk unstable psychiatric medical condition require high level care contraindication ketamine , MRI , PET</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>